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Genetic risk factors for type 2 diabetes mellitus and response
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Objective After the identification of type 2 diabetes
mellitus (T2DM) risk alleles from genome-wide association
studies, models have been developed to identify subjects
at high risk to develop T2DM. We hypothesize that a panel
of 20 repeatedly associated T2DM risk alleles influences
response to sulfonylureas (SUs).
Methods Two hundred and seven incident SU
(tolbutamide, glibenclamide, glimepiride, gliclazide) users
with T2DM were recruited from four primary care centers.
A genetic risk score per patient was calculated based on
the number of risk-alleles. With this score, patients were
categorized into three predefined genetic risk groups.
The effect of the genetic risk group on the achievement
of stable SU dose, prescribed stable SU dose, and time
to stable SU dose was analyzed.
Results Carriers of more than 17 T2DM risk alleles had a
1.7-fold reduced likelihood to achieve stable SU dose
(P = 0.044). No significant effect of the number of T2DM
risk alleles on prescribed dose was found. Carriers of more
than 17 T2DM risk alleles showed a marginally significant
increased time to stable dose (hazard ratio: 0.81; 95%
confidence interval, 0.75–1.01, P = 0.058).
Conclusion T2DM risk alleles are associated with
response to SUs in primary care T2DM patients. This
suggests that individualization of T2DM treatment
according to genetic profile may be an opportunity
to improve clinical outcome. Pharmacogenetics and
Genomics 21:461–468 c 2011 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
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Introduction
The incidence of type 2 diabetes mellitus (T2DM) is
increasing at an alarming rate. Worldwide, the number of
patients is expected to increase from 171 million in 2000
to 366 million in 2030 [1]. The therapeutic goal of
treating T2DM patients is to prevent or delay long-term
microvascular and macrovascular complications by achiev-
ing the best possible glycemic control.
Sulfonylureas (SUs) are part of the mainstay of treatment
with oral antidiabetic drugs. Tolbutamide, glibenclamide
(glyburide), gliclazide, and glimepiride are the most
commonly used representatives of this group. These
drugs act by closing the pancreatic b-cell potassium
channels, stimulating insulin secretion [2]. SUs are
initiated at a low dose and escalated to the optimal dose
with intervals of 2–4 weeks until the glycemic target
(HbA1c < 7%) is achieved. However, there is significant
interpatient variability in response to SUs, with approxi-
mately 10–20% of the patients experiencing primary
failure (decrease in fasting glucose level < 1.1 mmol/l)
and a similar percentage having an above average
response (mean reduction HbA1c 1.5–2%) [3–5].
With the completion of multiple genome-wide association
studies (GWAS) the knowledge of the complex genetic
background of T2DM has increased. These studies report
associations between genetic variants and the risk for the
development of T2DM. A panel of 20 T2DM associated
single nucleotide polymorphisms (SNPs) comprising 19
genes out of the GWAS data appears, that has been
replicated in several studies [6–17]. These SNPs are used
in models with the ultimate goal to identify subjects at
high risk to develop T2DM. Although marginally, the
addition of genetic information to clinical T2DM risk
factors increased the ability to predict future diabetes
[18–24].
From the panel of 20 T2DM risk-associated SNPs, the
majority is involved in the process of insulin release from
the pancreatic b-cells (Table 1). As SUs act by stimulat-
ing insulin secretion, response to SU treatment may also
be influenced by these genetic variants. Indeed, two of
the 19 T2DM risk-associated genes, encoding KCNJ11
and TCF7L2, have been previously correlated with
variation in SU response [4]. Furthermore, in subjects
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analyzed for genetic variation in the genes TCF7L2,
PPARG, FTO, KCNJ11, NOTCH2, WFS1, CDKAL1,
IGF2BP2, SLC30A8, JAZF1, HHEX, it was reported that
subjects with 12 or more T2DM risk alleles did not
increase their insulin secretion to compensate for the
increased insulin resistance as efficiently as those with 8
or less risk alleles [19]. Therefore, patients with a greater
number of risk alleles may show less response to SU
treatment and individualization of T2DM treatment
according to genetic profile may be an opportunity to
improve clinical outcome.
We hypothesize that the genetic variants associated with
the development of T2DM are also associated with
response to SU treatment. Therefore, we investigated
the effect of T2DM risk alleles on the response to SU
treatment in T2DM patients in a primary care setting.
Methods
Study setting
In the Netherlands the general practitioner (GP) plays a
central role in the provision of health care. Patients are
listed with one GP who is consulted for all healthcare
problems and indicates whether a referral to secondary
care is appropriate. Typically, the GP keeps an electronic
patient record (EPR) that covers all medical information
concerning the patient including prescription information
and reports from laboratories and specialists. GP’s have
adopted the practice guideline T2DM of the Dutch
College of General Practitioners [25]. Tailoring the
treatment to the individual patient is an important part
of the therapy.
Cohort ascertainment
A total of 207 T2DM patients from four university-
affiliated primary care centers (17 GPs) located in the
vicinity of Leiden, the Netherlands were recruited. The
ascertainment of the cohort has been described in detail
previously [26]. In brief, patients that had at least one
prescription of tolbutamide, glibenclamide, glimepiride,
or gliclazide between January 1992 and June 2008, were
at least 18 years of age and without insulin use at the time
of first SU prescription, and had at least 270 days of
follow-up registered in the EPR, were included. Ethnicity
was not routinely recorded in the EPR but most patients
in the Netherlands are from European ancestry. Patients
received a written invitation by mail from their GP. Of the
472 invited patients, 222 (47%) agreed to participate (see
Fig. S1, Supplemental digital content 1, http://links.lww.
com/FPC/A263, cohort ascertainment). After consent, a
saliva collection kit (DNA Genotek Inc., Ottawa, Ontario,
Canada) was mailed. The study was approved by the
ethics committee of the Leiden University Medical
Center.
Genotyping
We selected a panel of 20 SNPs in 19 genes that have
been associated with the development of T2DM in at
least three GWAS and were consistently replicated in
later studies aimed at estimating the predictive value of
these SNPs on the development of T2DM [6–24]. The
selected SNPs are listed in Table 1. DNA was isolated
from the saliva according to the protocol provided by the
manufacturer (DNA Genotek Inc.). Taqman genotyping
assays for 19 SNPs were designed by and obtained from
Applied Biosystems (Applied Biosystems, Nieuwerkerk
aan den IJssel, the Netherlands). SNP rs757210 could not
be designed as a Taqman genotyping assay and therefore
was genotyped by pyrosequencing (Isogen Life Science,
Maarssen, the Netherlands). Taqman genotyping assays
were performed on the LightCycler 480 II Real-Time
PCR System (Roche Diagnostics, Almere, the Nether-
lands) according to standard procedures. Genotyping
was performed without knowledge of the clinical data.
We obtained an average genotyping success rate of more
than 95%. As a quality control 5% of the samples were
Table 1 Selected single nucleotide polymorphisms associated with type 2 diabetes mellitus
Gene rs number Chromosome Risk allele Year Mechanism References
NOTCH2 rs10923931 1 T 2008 Unknown [9,19–24]
THADA rs7578597 2 T 2008 Unknown [9,19–24]
IGF2BP2 rs4402960 3 T 2007 b-cell dysfunction [8,9,11–13,18–24]
PPARG rs1801282 3 C 2000 Insulin sensitivity [8,9,11–13,19–24]
ADAMTS9 rs4607103 3 C 2008 Unknown [9,19–24]
WFS1 rs10010131 4 G 2007 Unknown [9,13,18–20,22,24]
CDKAL1 rs7754840 6 C 2007 b-cell dysfunction [7–9,11–13,18–24]
JAZF1 rs864745 7 A 2008 b-cell dysfunction [9,19–24]
SLC30A8 rs13266634 8 C 2007 b-cell dysfunction [7–9,11–14,18–24]
CDKN2A/CDKN2B rs10811661 9 T 2007 b-cell dysfunction [8,9,11–13,18–24]
rs564398 9 A [8,18,20,24]
TCF7L2 rs7903146 10 T 2006 b-cell dysfunction [7–9,11–14,18–24]
HHEX/IDE rs1111875 10 G 2007 b-cell dysfunction [7–9,11–14,18–24]
CDC123/CAMK1D rs12779790 10 G 2008 Unknown [9,19–24]
KCNJ11 rs5219 11 T 2003 b-cell dysfunction [8,9,11–13,19–24]
KCNQ1 rs2237892 11 C 2008 b-cell dysfunction [10,17,24]
MTNR1B rs10830963 11 G 2009 Disturbance of circadian rhythm [6,16,24]
TSPAN8/LGR5 rs7961581 12 C 2008 Unknown [9,19–24]
FTO rs8050136 16 A 2007 Obesity [8,9,11,13,19–22,24]
HNF-1b (TCF2) rs757210 17 A 2007 b-cell dysfunction [15,20,21,24]
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genotyped in duplicate for all assays and no inconsistencies
were observed. Five patients were excluded for quality
reasons (genotype call rate r 80%). All SNPs were in
Hardy–Weinberg equilibrium (P > 0.05), with the excep-
tion of rs2237892 (P = 0.011). This is most probably
ascribed to the very low minor allele frequency of
rs2237892, which was 0.025 in our study and comparable
with previously reported minor allele frequencies of
0.056–0.075 (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_
ref.cgi?rs = 2237892) accessed 5 October 2010.
Definition of effect
For each patient a cumulative genetic risk score was
calculated based on the number of present risk alleles.
Each person could have 0, 1, or 2 of them for each SNP,
resulting in a theoretical individual cumulative risk score
between 0 and 40. This approach assumes an equal and
additive effect of each allele on the risk of T2DM.
To allow categorization of patients, we predefined three
genetic risk groups on the basis of the frequency
distribution of risk alleles. We defined a low genetic risk
group and a high genetic risk group as the quintiles with
the lowest and highest number of T2DM risk alleles,
respectively. All other patients (three quintiles) were
categorized in the intermediate risk group.
The primary endpoint of our study is the effect of the
genetic risk group on achieving stable SU dose. Stable SU
dose was defined as the first period of more than or equal
to 270 consecutive days without SU dose adjustment, or
initiation or adjustment of therapy with other SUs,
insulin or metformin. If therapy with insulin was initiated
patients were censored. The period of more than or equal
to 270 days was chosen because prescriptions in the
Netherlands are limited to a maximum of 90 days and
more than or equal to 270 days equals three consecutive
prescriptions. Stable SU dose was calculated as normal-
ized dose by dividing the prescribed daily dose with the
standard daily dose used by the Pharmaceutical Aid
Committee of the Dutch Health Care Insurance Board
(10 mg glibenclamide; 1000 mg tolbutamide; 160 mg
gliclazide; 2 mg glimepiride). Secondary endpoints of
our study are the stable SU dose and the time required
for dose escalation (time to stable SU dose).
Statistical analysis
The data were analyzed using the SPSS statistical
package (version 16.0, SPSS, Chicago, Illinois, USA).
Deviation from Hardy–Weinberg equilibrium was tested
by the w2 test. Achievement of stable SU dose was
analyzed with the w2 test and multivariate logistic
regression analysis. Differences in mean stable SU dose
between genetic risk groups were analyzed using the
Kruskal–Wallis test and multivariate linear regression
analysis. Associations between the genetic risk groups and
time to stable SU dose were evaluated using the Cox
survival regression analysis. Before multivariate analysis,
all demographic and clinical variables were tested
univariately against the selected outcome. Variables with
a P value of 0.1 or less, age, and sex were selected for
multivariate analysis. All multivariate analyses were
corrected for age and sex.
Results
Data from 202 T2DM patients were available. The range
of the calculated genetic risk score was 10–26. The
quintiles with the lowest (r 17) and highest (Z 21)
number of T2DM risk alleles consisted of 59 patients
and 62 patients, respectively (Fig. 1). Table 2 presents
the characteristics of the 202 patients. There were no
differences between the different genetic risk groups
observed in any of the patient characteristics except for
age. Patients in the high-risk group were younger at the
time of first SU prescription compared with patients in
the low-risk and intermediate-risk group, respectively
(P = 0.001). Mean follow-up was 5.9 years, reflecting that
most patients (75.2%) were included after 2000. Our
patients received an average of 26 SU prescriptions
during the follow-up period with a median duration of 90
days per prescription.
The results of achieving stable SU dose and the T2DM
genetic risk groups are presented in Fig. 2. Of the patients,
148 (73.3%) achieved stable SU dose. The percentage of
Fig. 1
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Distribution of type 2 diabetes mellitus risk alleles and subsequent
classification in risk groups. Patients were categorized in three genetic
risk groups. Low-risk group; quintile with the lowest (r17) number of
T2DM risk alleles. High-risk group; quintile with the highest (Z21)
number of T2DM risk alleles. Remaining patients were categorized in
the intermediate-risk group (18–20 T2DM risk alleles).
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patients achieving stable SU dose was lower in the
high-risk group compared with the intermediate-risk and
low-risk groups (61.3 vs. 74.1 vs. 84.7%, respectively,
P = 0.004). In the multivariate logistic regression analysis
age at first SU prescription, the concomitant use of
metformin, and the T2DM genetic risk group were
independently significantly associated with achieving
stable SU dose (Table 3). The regression model
explained 28.7% of the variation in achievement of stable
dose. Data show that patients with a higher T2DM risk
had a 1.7-fold reduced likelihood to achieve stable SU
dose (P = 0.044).
Next, the mean SU starting dose was analyzed. The mean
SU starting dose for all patients was 0.61 (95% CI: 0.58–
0.65). As expected, no differences in SU starting dose
were found between the different genetic risk groups. No
differences in mean stable SU dose were found between
the different T2DM genetic risk groups [low-risk group
0.90, 95% confidence interval (CI) 0.75–1.05 vs. inter-
mediate-risk group 0.84, 95% CI: 0.74–0.94 vs. high-risk
group 0.95, 95% CI: 0.72–1.17, P = 0.97]. In multivariate
linear regression, only the effect of the SU starting dose
and sex were independently significant associated with
stable SU dose, whereas the genetic risk group for T2DM
was not associated with stable SU dose.
As SUs are escalated to the optimal dose, the effect of
the genetic risk group on time to stable SU dose was
evaluated. Carriers of the high-risk genetic profile
(Z 21 risk alleles) had a two-fold and five-fold longer
time to stable dose compared with patients with the
intermediate risk (18–20 risk alleles) and low-risk profile
(r 17 risk alleles) (median time to stable SU dose 160 vs.
59 vs. 31 days, respectively, P = 0.007). In a multivariate
Cox regression analysis including the factors such as age
Table 2 Characteristics of the 202 patients with type 2 diabetes mellitus in primary care
Genetic risk group
Variable no. (%)a All patients Low-risk Intermediate-risk High-risk P value
Subjects 202 59 (29.2) 81 (40.1) 62 (30.7) NA
Men 106 (52.5) 30 (50.8) 45 (55.6) 31 (50.0) 0.77
Women 96 (47.5) 29 (49.2) 36 (44.4) 31 (50.0)
Age in years, mean (SD) 61.4 (10.7) 64.0 (9.5) 62.6 (10.4) 57.3 (11.1) 0.001
Follow-up in years, mean (SD) 5.9 (3.0) 6.0 (3.0) 5.7 (3.0) 6.2 (3.0) 0.52
Visits in year one (SD) 9.6 (4.7) 8.6 (3.7) 10.0 (5.2) 10.0 (4.6) 0.35
Metformin use 62 (30.7) 18 (30.5) 27 (33.3) 17 (27.4) 0.75
Primary sulfonylurea 0.098b
Glibenclamide 12 (5.9) 7 (11.9) 1 (1.2) 4 (6.5)
Tolbutamide 85 (42.1) 18 (30.5) 41 (50.6) 26 (41.9)
Gliclazide 24 (11.9) 7 (11.9) 10 (12.3) 7 (11.3)
Glimepiride 81 (40.1) 27 (45.8) 29 (35.8) 25 (40.3)
Low-risk group; patients with 17 or less risk alleles. Intermediate-risk group: patients with 18–20 risk alleles. High-risk group; patients with at least 21 risk alleles.
NA, not applicable; SD, standard deviation.
aUnless stated otherwise.
bw2 for primary sulfonylurea vs. genetic risk group.



























χ2 P = 0.004
Percentage of type 2 diabetes mellitus patients that reached stable sulfonylurea dose. Low-risk group; patients with 17 or less risk alleles.
Intermediate-risk group: patients with 18–20 risk alleles. High-risk group; patients with at least 21 risk alleles.
464 Pharmacogenetics and Genomics 2011, Vol 21 No 8
on first SU prescription, sex, and the concomitant use of
metformin, patients with a higher number of risk alleles
showed a marginally significant increased time to stable
SU dose (hazard ratio: 0.81; 95% CI: 0.75–1.01,
P = 0.058) (Fig. 3).
Discussion
To the best of our knowledge, this is the first study
exploring the relationship between response to treatment
with SUs and T2DM risk alleles. In this retrospective
cohort study of 202 T2DM patients, patients with more
than 17 risk alleles have a 1.7-fold reduced likelihood to
achieve a stable SU dose. These patients also show a
marginally significant increased time to achieve stable SU
dose compared with carriers of less than 17 risk alleles.
However, the number of T2DM risk alleles does not
seem to affect the average stable SU dose used. There-
fore, our data suggest that patients with a higher number
of T2DM risk alleles have a decreased and delayed
response to SU treatment.
Drug response is determined by both pharmacokinetics
and pharmacodynamics of a drug. Several groups have
investigated genetic variation in genes affecting the
pharmacokinetics of SU response. Two variants in CYP2C9,
CYP2C9*2 and CYP2C9*3, have been associated with a
decreased SU metabolism in healthy volunteers [27]. Five
studies assessed the effect of these polymorphisms in
T2DM patients. Presence of the CYP2C9*3 allele was
associated with an increased risk for hypoglycemia [28,29].
Tolbutamide users with a CYP2C9*2 or CYP2C9*3 allele
have been shown to have a significantly lower dose
escalation compared with homozygous carriers of the
CYP2C9*1 allele [30]. In a large cohort of 1073 incident
SU users with T2DM Zhou et al. [31] found that carriers
of the CYP2C9*2 or CYP2C9*3 allele were less likely
to fail on SU monotherapy. In a recent study we found
no statistically significant effect of the CYP2C9*2 or
CYP2C9*3 allele on the prescribed stable dose [26].
Variation in genes associated with the pharmacodynamics
of SUs in T2DM patients has received considerably less
attention. Genetic variants associated with SU response
have been described for some monogenic forms of
diabetes [32–34]. For polygenic T2DM, variants in the
genes KCNJ11, TCF7L2, ABCC8, IRS1, and NOS1AP have
been associated with SU response [35–38]. Of these,
only the genes KCNJ11 and TCF7L2 were reported to
contribute to an increased risk for T2DM in published
GWAS. KCNJ11 encodes the Kir6.2 subunit, one of the
two subunits that form the ATP-sensitive potassium
channel involved in insulin release. Carriership of the
E23K variant of the KCNJ11 gene has been associated
with failure to SU therapy, but there are some conflicting
results [39–41]. Variants in the TCF7L2 gene have also
been associated with SU response. In a study with 901
incident SU users, patients with the TT genotype for
rs7903146 were 1.73 times less likely to be treated to
lower a target HbA1c of 7% in the first 3–12 months of
treatment compared with patients with the CC genotype
[42]. For a variant in linkage with rs7903146 an even
larger effect (odds ratio = 1.95) was reported. In this
study, none of the individual risk alleles were significantly
associated with the achievement of stable dose (see Table
S2, Supplemental digital content 2, http://links.lww.com/
FPC/A264), risk allele frequency and association with
Table 3 Analysis of factors relevant for achieving stable sulfonylurea dose in patients with type 2 diabetes mellitus in primary care
Univariate Multivariatea
Factor OR 95% CI R2 P value OR 95% CI P value
Constant 1.81 NA 0.654
Male vs. female sex 1.55 0.83–2.91 0.009 0.17 1.54 0.72–3.29 0.262
Effect of age (per year increase) 1.06 1.03–1.09 0.069 < 0.001 1.04 1.00–1.08 0.036
Metformin use vs. no metformin use at stable sulfonylurea dose 0.07 0.03–0.16 0.238 < 0.001 0.07 0.03–0.17 < 0.001
Genetic risk group (low-risk - intermediate-risk - high-risk group) 0.54 0.35–0.82 0.042 0.004 0.59 0.35–0.99 0.044
-, stepwise increase from low-risk to intermediate-risk to high-risk group; CI, confidence interval; OR, odds ratio; R2, variation in the achievement of stable dose.
aR2 for the complete model was 0.287.
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Multivariate Cox regression analysis plots of time to the first stable dose
of sulfonylureas in type 2 diabetes mellitus patients in primary care.
Low-risk group (–––); patients with 17 or less risk alleles. Intermediate-
risk group (- - -); patients with 18–20 risk alleles. High-risk group (–––);
patients with at least 21 risk alleles.
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achievement of stable SU dose of the individual SNPs).
This is most likely due to the limited sample size of our
study and the probable small effect size of the individual
risk alleles.
Our study has some limitations. No data were available
for patients that switched to another GP or who died after
1992. Therefore, we cannot completely rule out the
possibility of selection bias, although this is conceptually
very unlikely. A nonresponse analysis with age, sex, type
of first prescribed SU, metformin use, and GP showed no
differences between participants and patients who did
not consent to our study, suggesting that no selection bias
has occurred on any of these parameters.
We selected stable SU dose as the primary endpoint of
our analysis. Ideally macrovascular (e.g. diabetes-related
death or myocardial infarction) or microvascular events
(e.g. retinopathy or renal failure) would have been used.
Alternatively, biomarkers related to these events, such as
HbA1c or fasting plasma glucose (FPG) might have been
used. However, as data concerning these parameters were
not routinely recorded in the EPR, data were too sparse
to be used in our analysis. Therefore, we selected stable
SU dose as an alternative. Although, no SU pharmaco-
genetics studies have used stable SU dose as endpoint,
this parameter closely reflects actual clinical practice.
The time to stable SU dose analysis assumes that GPs
adhere to the T2DM guideline of the Dutch College
of General Practitioners and titrate SU dose in response
to glucose and HbA1c levels. We have three arguments
that support our assumption. Firstly, mean FPG was
7.77 mmol/l (95% CI: 7.42–8.12, n = 95) for the subgroup
of patients with a FPG measurement available during
stable SU dose. Secondly, the adherence of GPs to
guidelines is reported to be good in the Netherlands [43].
Finally, even if GPs do not adhere to the T2DM
guideline, and bias would be introduced to our analysis,
there is no reason to assume that the nonadherence of
GPs is not divided randomly over the different genetic
risk groups. Therefore, possible nonadherence does not
affect the comparison of the time to stable dose between
the different genetic risk groups but can only affect the
absolute results of this analysis.
There are multiple known factors that predict a good
response to SUs including baseline HbA1c, recently
diagnosed diabetes, mild-to-moderate fasting hyper-
glycemia (< 12.2–13.3 mmol/l), good b-cell function (high
fasting C-peptide level), no history of insulin therapy,
and absence of islet cell or glutamic acid decarboxylase
antibodies [3]. However, for none of these factors
sufficient data were available in our retrospective cohort
study and we were unable to account for their effect. In
addition, the available data on weight, a factor that is
associated with the onset of T2DM, were too sparse to be
included in the analysis as a covariate. As a consequence
we cannot rule out that patients with a higher number of
risk alleles also have a more severe form of T2DM that
might confer to an a priori decreased probability to
achieve stable SU dose. In our opinion, the only way to
collect sufficient high quality data that cover all of these
parameters would be to conduct a prospective observa-
tional study. Ideally such a study would include two
treatment arms with pharmacological different drugs or
placebo. Such a design would allow differentiating
between the effect of T2DM risk alleles on disease
progression and effect on treatment.
The results of different SUs were pooled in one analysis.
Although SUs are generally reported to have equipotent
glucose lowering effects when administered in maximally
effective doses [3,5], it would be interesting to investi-
gate if our hypothesis is valid for each of the individual
SUs. However, due to the sample size of our study such a
subgroup analysis was not possible.
We achieved a high success rate of genotyping with a call
rate of more than 95% for all individual SNPs. After
exclusion of five patients with a call rate of less than or
equal to 80, 0.9% of the genotype data were missing.
Missing genotype data were replaced with a risk score
of 0. To test the sensitivity of our analysis for this
replacement, we reanalyzed the data using two alter-
native approaches. First, as for some SNPs the wild-type
allele is the risk allele, missing data were replaced with
the score of the wild-type allele. As a result, two patients
were reclassified from the low-risk to the intermediate-
risk group, and one patient was reclassified from the
intermediate-risk group to the high-risk group. Secondly,
we excluded all patients with any missing data, resulting
in the exclusion of an additional 31 (15.3%) patients.
Similar results on all end points were obtained with
all approaches, except for the effect of the genetic risk
score that lost statistical significance in multivariate
analysis after exclusion of all patients with missing
data. These sensitivity analyses indicate that our results
are valid.
The analysis of the effect of the genetic risk score on
SU response assumes that each risk allele has an equal
and additive effect, both within and between loci. This
is clearly a simplification of the mechanism leading to
variation of SU response. However, this approach is used
in all GWAS studies concerning prediction of T2DM.
Until it is clear what the true effect size of individual risk
alleles is, the additive genetic model is probably the most
appropriate and consistent method to analyze T2DM
genetic data.
We chose to compare the quintile with the lowest (r 17,
n = 59, low-risk group) and highest (Z 21, n = 62, high-
risk group) number of T2DM risk alleles, whereas
patients with 18–20 risk alleles were pooled in one group
(n = 81, intermediate-risk group) (Fig. 1). The use of
quintiles was based on a study by Lyssenko et al. [19] and
allows potentially easy translation to the clinic by clear
466 Pharmacogenetics and Genomics 2011, Vol 21 No 8
classification of T2DM patients. The cutoffs for the
quintiles with the highest and lowest number of T2DM
risk alleles fell within the group of patients with 21 and
17 risk alleles respectively. We categorized patients with
17 risk alleles to the low-risk group and 21 alleles to the
high-risk group, resulting in a slightly larger number of
patients in both categories than anticipated. To ascertain
that our results are not solely due to study design, we also
analyzed the genetic risk score as a continuous variable
instead of the analysis of risk groups. Next to this genetic
risk score (range 10–26), sex, age on first SU prescription,
and the use of metformin were included in the multi-
variate analysis. Data showed similar results for both the
effect size and direction for the genetic risk score (odds
ratio 0.88 95% CI: 0.76–1.02, P = 0.11). This suggests
that with increasing number of risk alleles, the chance of
achieving stable SU dose decreases.
The concept of disease-related genes influencing re-
sponse to treatment is not new. For example, variation in
the gene coding for the 5-hydroxytryptamine 2A receptor
has been associated with variation of clozapine response
and increased susceptibility to schizophrenia [44,45].
Variation in the gene coding for the b-2-adrenergic
receptor has been associated with airway responsiveness
to b-2-receptor agonists and susceptibility to lower airway
reactivity in patients with asthma [46,47]. Our results
show that patients with a higher number of risk alleles
were younger at the date of their first SU prescription.
This may be the result of a more ‘aggressive’ form of
T2DM. For many complex diseases such as T2DM, there
may be multiple genetic backgrounds resulting in similar
phenotypic disease, each requiring a different drug
treatment. Our results support this concept, and support
the use of disease-related genes in pharmacogenetic
studies. We should emphasize, however, the fact that
we have only begun to unravel the genetic determinants
of drug response in T2DM and that although many of
the genes are associated with b-cell function, the exact
mechanism behind our finding remains unclear. Our
results do provide some ‘proof of principle’ that the
complex background of T2DM may ultimately result in
the identification of different genetic subgroups of
T2DM patients that require different pharmacotherapy.
However, replication in an independent cohort and
further elucidation of the causal mechanisms underlying
SU response are warranted.
In conclusion, T2DM-associated risk alleles are asso-
ciated with response to SU treatment in primary care
T2DM patients. This suggests that individualization of
T2DM treatment according to genetic profile may be an
opportunity to improve clinical outcome.
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